Base-Edited CAR-T Cells Drive Deep Remission in Resistant Leukemia

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive blood cancer, and when it returns after standard treatment, options are few and outcomes grim. A study published on 11 December 2025 in the New England Journal of Medicine, and presented at the 67th American Society of Hematology Annual Meeting, offers striking new hope: a gene-edited cell therapy called BE-CAR7 drove deep remissions in most patients who had run out of other choices.

BE-CAR7 is built using base editing, an advanced form of CRISPR that rewrites individual DNA letters with high precision. Researchers at University College London and Great Ormond Street Hospital used it to engineer "universal," off-the-shelf CAR-T cells from healthy-donor cells. By removing the CD7 and CD52 markers, the edited cells no longer attack each other during manufacturing and can survive the antibody drugs given to quiet the patient's immune system — solving problems that had long stymied CAR-T therapy for T-cell cancers.

“A study published on 11 December 2025 in the New England Journal of Medicine, and presented at the 67th American Society of Hematology Annual Meeting, offers striking new hope: a gene-edited cell therapy called BE-CAR7 drove deep remissions in most patients who had run out of other choices.”

The results were powerful. Across 10 patients — eight children and two adults treated at Great Ormond Street and King's College Hospital — 82% achieved very deep remission within about four weeks of a single infusion, clearing the way for a stem-cell transplant to consolidate the cure. Some 64% remain disease-free, and the earliest patients have been disease-free and off therapy for three years. "We've shown that universal or 'off the shelf' base-edited CAR T-cells can seek and destroy very resistant cases of CD7+ leukemia," said Professor Waseem Qasim of UCL. Alyssa Tapley, the first person in the world to receive the therapy in 2022 at age 13, is now 16.

Caution is warranted, as the researchers themselves stress. This was an early-phase study in a small number of very sick patients, most went on to a transplant, and longer follow-up is needed to confirm how durable the benefit is and to fully understand the risks. The complex manufacturing also raises questions about access. Even so, watching a precision gene-editing tool turn a once-untreatable leukemia into deep, lasting remission marks a genuine leap forward — and a vivid example of how editing the genome is beginning to rewrite the odds for patients who had almost none.